Yi Yan Hong, MD
Interventional Pain Management · Johnstown, PANPI 1235296039
Payments from drug & device makers
Across 24 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$250
- Virtus Pharmaceuticals LLC$73
- Amgen$57
- Pfizer$34
- AbbVie$21
- Redhill Biopharma Inc.$19
- plus $29 from 2 others
What the payments were for
- Food & beverage$483100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 13 | $250 |
| Virtus Pharmaceuticals LLC | 4 | $73 |
| Amgen | 1 | $57 |
| Pfizer | 2 | $34 |
| AbbVie | 1 | $21 |
| Redhill Biopharma Inc. | 1 | $19 |
| AstraZeneca | 1 | $17 |
| Protega Pharmaceutials Inc | 1 | $12 |
How this compares
Too few interventional pain management providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 87 | $71,048 |
| OxycontinOxycodone Hcl | 50 | $56,150 |
| Oxymorphone Hcl ErOxymorphone Hcl | 48 | $54,944 |
| Fentanyl | 256 | $34,273 |
| Oxycodone Hcl | 734 | $19,621 |
| Oxymorphone Hcl | 22 | $11,820 |
| Morphine Sulfate ErMorphine Sulfate | 231 | $7,118 |
| MovantikNaloxegol Oxalate | 15 | $5,753 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 259 | $5,542 |
| Morphine Sulfate | 80 | $2,367 |
| Gabapentin | 245 | $2,282 |
| Methadone Hcl | 75 | $2,088 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 142 | $1,986 |
| Pregabalin | 111 | $1,257 |
| Baclofen | 125 | $1,184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $250 | $71,04887 claims |
| Redhill Biopharma Inc.Movantik | $19 | $5,75315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional pain management providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.
Other interventional pain management in Johnstown
- John HanDanville$0
- Shaik Mohd AhmedDanville$0
- Abdelhamed RagabDanville$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.